ByTrending Posts
Is Aidoc Driving Clinical Adoption of AI in…
Executive Summary Aidoc, a pioneer in AI-assisted radiology and diagnostic workflow automation, continues to expand its footprint in…
Is Viz.ai Transforming Medical Diagnostics and Acute Care…
Executive Summary Viz.ai, a leader in AI‑enabled clinical diagnostics and workflow orchestration, is reshaping how acute care conditions—especially…
Is NVIDIA Powering the AI Revolution in Medical…
Executive Summary NVIDIA, the global leader in accelerated computing and AI infrastructure, is increasingly at the core of…
Did NVIDIA Become the Central AI Catalyst for…
2025 marked a pivotal year for artificial intelligence in biopharma. As life sciences companies moved beyond isolated AI…
Which AI Biopharma Startups Truly Won in 2025—And…
Executive Perspective 2025 marked a decisive shift for AI biopharma startups—from experimental promise to measurable strategic impact. Success…
Is Nabla Bio Redefining AI-Driven Protein Engineering as…
Executive Summary Nabla Bio is emerging as a next-generation AI biotech focused on computationally driven protein and antibody…
Is AbCellera Biologics Building a Durable AI Antibody…
Executive Summary AbCellera Biologics has established itself as a global leader in AI-driven antibody discovery, combining advanced computational…
Is Recursion Pharmaceuticals Setting the Standard for AI-Powered…
Executive Summary Recursion Pharmaceuticals has emerged as a leading clinical-stage TechBio company applying artificial intelligence, automation, and large-scale…
Can ReviR’s AI-Powered RNA Modulation Platform Convert $50M+…
Executive Summary ReviR Therapeutics continues to establish itself as a leader in RNA-targeting small molecule drug discovery, advancing…
Trending Posts
Latest Stories
Eli Lilly to Acquire Orna Therapeutics in Deal Valued at Up to $2.4 Billion to Advance In Vivo Cell Therapy Platform
Indianapolis, IN – February 9, 2026 – Eli Lilly and Company today announced it has…
AstraZeneca Reports 2025 Performance with Strong Brand Momentum Across Core Therapeutic Areas
AstraZeneca today announced its full-year 2025 results, reflecting continued growth across oncology, cardiovascular-renal-metabolism (CVRM), respiratory…
GSK Reports Full-Year 2025 Results with Strategic Portfolio Focus
GSK today reported its full-year performance for 2025 and outlined its strategic approach to long-term…
Roche Reports Full-Year 2025 Results and Provides Strategic Portfolio Insights
Roche today announced its full-year 2025 performance and outlined its strategic positioning across key therapeutic…
Gallery
